Zacks Research Analysts Reduce Earnings Estimates for Eli Lilly and Company (NYSE:LLY)

Eli Lilly and Company (NYSE:LLY) – Equities researchers at Zacks Research reduced their Q1 2026 earnings per share (EPS) estimates for shares of Eli Lilly and Company in a research note issued on Wednesday, April 17th. Zacks Research analyst K. Shah now forecasts that the company will post earnings per share of $6.06 for the quarter, down from their previous estimate of $6.11. The consensus estimate for Eli Lilly and Company’s current full-year earnings is $12.52 per share. Zacks Research also issued estimates for Eli Lilly and Company’s FY2026 earnings at $24.44 EPS.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.30 by $0.19. The company had revenue of $9.35 billion for the quarter, compared to the consensus estimate of $8.95 billion. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The firm’s quarterly revenue was up 28.1% on a year-over-year basis. During the same quarter last year, the company earned $2.09 EPS.

Several other analysts also recently issued reports on LLY. TheStreet raised Eli Lilly and Company from a “c+” rating to a “b” rating in a research note on Friday, March 8th. Wells Fargo & Company raised their price target on Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a report on Tuesday, February 6th. Bank of America raised their price target on Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a “buy” rating in a report on Friday, March 1st. Barclays raised their price target on Eli Lilly and Company from $680.00 to $810.00 and gave the company an “overweight” rating in a report on Wednesday, February 7th. Finally, JPMorgan Chase & Co. raised their price target on Eli Lilly and Company from $775.00 to $850.00 and gave the company an “overweight” rating in a report on Friday, March 15th. Three equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $728.05.

Eli Lilly and Company Stock Down 2.6 %

Shares of LLY opened at $726.31 on Friday. The business’s 50 day moving average is $763.96 and its 200 day moving average is $659.59. The company has a market capitalization of $690.11 billion, a PE ratio of 125.23, a price-to-earnings-growth ratio of 1.64 and a beta of 0.34. Eli Lilly and Company has a 12-month low of $369.76 and a 12-month high of $800.78. The company has a current ratio of 0.94, a quick ratio of 0.73 and a debt-to-equity ratio of 1.69.

Hedge Funds Weigh In On Eli Lilly and Company

A number of large investors have recently bought and sold shares of LLY. Norges Bank purchased a new position in Eli Lilly and Company during the 4th quarter valued at $5,992,890,000. International Assets Investment Management LLC raised its position in Eli Lilly and Company by 61,268.8% during the 4th quarter. International Assets Investment Management LLC now owns 7,342,780 shares of the company’s stock valued at $42,802,530,000 after purchasing an additional 7,330,815 shares in the last quarter. Moneta Group Investment Advisors LLC raised its position in Eli Lilly and Company by 102,752.2% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 5,446,026 shares of the company’s stock valued at $1,992,374,000 after purchasing an additional 5,440,731 shares in the last quarter. Morgan Stanley raised its position in Eli Lilly and Company by 44.1% during the 4th quarter. Morgan Stanley now owns 12,059,204 shares of the company’s stock valued at $4,411,740,000 after purchasing an additional 3,691,436 shares in the last quarter. Finally, Imprint Wealth LLC raised its position in Eli Lilly and Company by 53,716.8% during the 2nd quarter. Imprint Wealth LLC now owns 1,751,200 shares of the company’s stock valued at $175,120,000 after purchasing an additional 1,747,946 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Insider Transactions at Eli Lilly and Company

In related news, major shareholder Lilly Endowment Inc sold 54,032 shares of the business’s stock in a transaction on Monday, January 29th. The stock was sold at an average price of $645.07, for a total transaction of $34,854,422.24. Following the completion of the transaction, the insider now owns 99,488,598 shares in the company, valued at approximately $64,177,109,911.86. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 0.13% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.